Free Trial
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free SPEC Stock Alerts

INSPECS Group (SPEC) Competitors

INSPECS Group logo
GBX 82 -2.50 (-2.96%)
As of 10:54 AM Eastern
Compare

SPEC vs. TSTL, BVC, AKR, ODX, and CNSL

Should you buy INSPECS Group stock or one of its competitors? MarketBeat compares INSPECS Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with INSPECS Group include Tristel (TSTL), BATM Advanced Communications (BVC), Akers Biosciences (AKR), Omega Diagnostics Group (ODX), and Cambridge Nutritional Sciences (CNSL). These companies are all part of the "medical instruments & supplies" industry.

How does INSPECS Group compare to Tristel?

INSPECS Group (LON:SPEC) and Tristel (LON:TSTL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

INSPECS Group has a beta of 1.674, indicating that its share price is 67% more volatile than the broader market. Comparatively, Tristel has a beta of 0.333, indicating that its share price is 67% less volatile than the broader market.

Tristel has a net margin of 15.88% compared to INSPECS Group's net margin of -2.67%. Tristel's return on equity of 23.64% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-2.67% -6.07% 0.45%
Tristel 15.88%23.64%9.89%

In the previous week, INSPECS Group's average media sentiment score of 0.00 equaled Tristel'saverage media sentiment score.

Company Overall Sentiment
INSPECS Group Neutral
Tristel Neutral

INSPECS Group currently has a consensus price target of GBX 60, indicating a potential downside of 26.83%. Tristel has a consensus price target of GBX 400, indicating a potential upside of 3.49%. Given Tristel's higher possible upside, analysts clearly believe Tristel is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Tristel
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

0.4% of INSPECS Group shares are owned by institutional investors. Comparatively, 21.6% of Tristel shares are owned by institutional investors. 21.0% of INSPECS Group shares are owned by company insiders. Comparatively, 21.0% of Tristel shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Tristel has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£191.70M0.43-£4.11M-£9.40N/A
Tristel£49.54M3.74£6.54M£16.2423.80

Summary

Tristel beats INSPECS Group on 10 of the 14 factors compared between the two stocks.

How does INSPECS Group compare to BATM Advanced Communications?

INSPECS Group (LON:SPEC) and BATM Advanced Communications (LON:BVC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

BATM Advanced Communications has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than BATM Advanced Communications, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£191.70M0.43-£4.11M-£9.40N/A
BATM Advanced Communications£123.20M0.37-£278.26K-£4.20N/A

In the previous week, BATM Advanced Communications had 1 more articles in the media than INSPECS Group. MarketBeat recorded 1 mentions for BATM Advanced Communications and 0 mentions for INSPECS Group. BATM Advanced Communications' average media sentiment score of 0.66 beat INSPECS Group's score of 0.00 indicating that BATM Advanced Communications is being referred to more favorably in the news media.

Company Overall Sentiment
INSPECS Group Neutral
BATM Advanced Communications Positive

0.4% of INSPECS Group shares are held by institutional investors. Comparatively, 16.6% of BATM Advanced Communications shares are held by institutional investors. 21.0% of INSPECS Group shares are held by insiders. Comparatively, 31.0% of BATM Advanced Communications shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

INSPECS Group has a net margin of -2.67% compared to BATM Advanced Communications' net margin of -14.90%. INSPECS Group's return on equity of -6.07% beat BATM Advanced Communications' return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-2.67% -6.07% 0.45%
BATM Advanced Communications -14.90%-22.13%0.58%

INSPECS Group presently has a consensus target price of GBX 60, suggesting a potential downside of 26.83%. Given INSPECS Group's higher possible upside, analysts clearly believe INSPECS Group is more favorable than BATM Advanced Communications.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
BATM Advanced Communications
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

INSPECS Group has a beta of 1.674, meaning that its stock price is 67% more volatile than the broader market. Comparatively, BATM Advanced Communications has a beta of 0.727, meaning that its stock price is 27% less volatile than the broader market.

Summary

BATM Advanced Communications beats INSPECS Group on 8 of the 14 factors compared between the two stocks.

How does INSPECS Group compare to Akers Biosciences?

Akers Biosciences (LON:AKR) and INSPECS Group (LON:SPEC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

Akers Biosciences has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Akers Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akers Biosciences£2.32M0.00N/A-£129.60N/A
INSPECS Group£191.70M0.43-£4.11M-£9.40N/A

0.4% of INSPECS Group shares are held by institutional investors. 21.0% of INSPECS Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Akers Biosciences' average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company Overall Sentiment
Akers Biosciences Neutral
INSPECS Group Neutral

Akers Biosciences has a net margin of 0.00% compared to INSPECS Group's net margin of -2.67%. Akers Biosciences' return on equity of 0.00% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Akers BiosciencesN/A N/A N/A
INSPECS Group -2.67%-6.07%0.45%

INSPECS Group has a consensus target price of GBX 60, suggesting a potential downside of 26.83%. Given Akers Biosciences' higher probable upside, equities analysts clearly believe Akers Biosciences is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akers Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

INSPECS Group beats Akers Biosciences on 7 of the 11 factors compared between the two stocks.

How does INSPECS Group compare to Omega Diagnostics Group?

Omega Diagnostics Group (LON:ODX) and INSPECS Group (LON:SPEC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

In the previous week, Omega Diagnostics Group's average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company Overall Sentiment
Omega Diagnostics Group Neutral
INSPECS Group Neutral

INSPECS Group has a consensus target price of GBX 60, indicating a potential downside of 26.83%. Given Omega Diagnostics Group's higher possible upside, research analysts plainly believe Omega Diagnostics Group is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Omega Diagnostics Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Omega Diagnostics Group has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Omega Diagnostics Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Omega Diagnostics Group£7.55M0.00-£3.17M-£0.01N/A
INSPECS Group£191.70M0.43-£4.11M-£9.40N/A

INSPECS Group has a net margin of -2.67% compared to Omega Diagnostics Group's net margin of -51.15%. INSPECS Group's return on equity of -6.07% beat Omega Diagnostics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Omega Diagnostics Group-51.15% -29.14% -10.53%
INSPECS Group -2.67%-6.07%0.45%

Omega Diagnostics Group has a beta of 3.85, indicating that its stock price is 285% more volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.674, indicating that its stock price is 67% more volatile than the broader market.

29.8% of Omega Diagnostics Group shares are held by institutional investors. Comparatively, 0.4% of INSPECS Group shares are held by institutional investors. 50.6% of Omega Diagnostics Group shares are held by insiders. Comparatively, 21.0% of INSPECS Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

INSPECS Group beats Omega Diagnostics Group on 7 of the 13 factors compared between the two stocks.

How does INSPECS Group compare to Cambridge Nutritional Sciences?

Cambridge Nutritional Sciences (LON:CNSL) and INSPECS Group (LON:SPEC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

INSPECS Group has a consensus target price of GBX 60, suggesting a potential downside of 26.83%. Given INSPECS Group's stronger consensus rating and higher possible upside, analysts clearly believe INSPECS Group is more favorable than Cambridge Nutritional Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cambridge Nutritional Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Cambridge Nutritional Sciences has a beta of 2.101, suggesting that its share price is 110% more volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.674, suggesting that its share price is 67% more volatile than the broader market.

Cambridge Nutritional Sciences has a net margin of 16.94% compared to INSPECS Group's net margin of -2.67%. Cambridge Nutritional Sciences' return on equity of 12.15% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Cambridge Nutritional Sciences16.94% 12.15% -2.36%
INSPECS Group -2.67%-6.07%0.45%

1.6% of Cambridge Nutritional Sciences shares are owned by institutional investors. Comparatively, 0.4% of INSPECS Group shares are owned by institutional investors. 7.8% of Cambridge Nutritional Sciences shares are owned by company insiders. Comparatively, 21.0% of INSPECS Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Cambridge Nutritional Sciences' average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company Overall Sentiment
Cambridge Nutritional Sciences Neutral
INSPECS Group Neutral

Cambridge Nutritional Sciences has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Cambridge Nutritional Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cambridge Nutritional Sciences£8.06M0.56-£3.03M£0.603.17
INSPECS Group£191.70M0.43-£4.11M-£9.40N/A

Summary

Cambridge Nutritional Sciences beats INSPECS Group on 8 of the 14 factors compared between the two stocks.

Get INSPECS Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPEC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPEC vs. The Competition

Export
MetricINSPECS GroupMedical Instruments & Supplies IndustryMedical SectorLON Exchange
Market Cap£83.37M£2.79B£6.50B£2.80B
Dividend Yield2.00%2.03%2.67%6.18%
P/E Ratio-8.7216.4324.01366.95
Price / Sales0.4372.15540.5586,520.47
Price / Cash1.63146.5427.4827.85
Price / Book0.822.2210.557.82
Net Income-£4.11M£99.80M£3.56B£5.89B
7 Day Performance-0.67%0.13%1.54%0.86%
1 Month Performance-2.38%2.73%2.48%1.94%
1 Year Performance72.63%-8.91%26.49%73.86%

INSPECS Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPEC
INSPECS Group
0.3644 of 5 stars		GBX 82
-3.0%		GBX 60
-26.8%		+77.9%£83.37M£191.70MN/A1,673
TSTL
Tristel
N/AGBX 381
+1.6%		GBX 400
+5.0%		+1.4%£182.62M£49.54M23.46208
BVC
BATM Advanced Communications
1.1266 of 5 stars		GBX 12.60
-0.4%		N/A-22.3%£42.85M£123.20MN/A980
AKR
Akers Biosciences
N/AN/AN/AN/A£21.64M£2.32MN/A120
ODX
Omega Diagnostics Group
N/AN/AN/AN/A£5.23M£7.55MN/A91

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:SPEC) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
Porter flew 3,300 miles to investigate this system
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Elon’s new "tollbooth"
The upcoming SpaceX IPO - reported for June 12 - is valued at $1.75 trillion. But one analyst says fighting ov...
Weiss Ratings | Sponsoredtc pixel